JIM CRAMERAll the Right Moves: Cramer's 'Mad Money' Recap (Tuesday 1/14/20)By Scott RuttJan 14, 2020 8:38 PM EST
PRESS RELEASESRevance Announces Pricing Of $250 Million Of Convertible Senior Notes Due 2027By Business WireFeb 12, 2020 6:55 AM EST
PRESS RELEASESRevance Announces Proposed Private Offering Of $200 Million Of Convertible Senior Notes Due 2027By Business WireFeb 10, 2020 4:08 PM EST
PRESS RELEASESRevance Announces U.S. FDA Acceptance Of Biologics License Application (BLA) For DAXI To Treat Glabellar (Frown) LinesBy Business WireFeb 6, 2020 8:00 AM EST
JIM CRAMERAll the Right Moves: Cramer's 'Mad Money' Recap (Tuesday 1/14/20)By Scott RuttJan 14, 2020 8:38 PM EST
PRESS RELEASESRevance Announces Transformative Aesthetics Portfolio Transaction With Exclusive U.S. Distribution Agreement Of FDA-Approved Dermal Fillers From TEOXANE SABy Business WireJan 10, 2020 8:05 AM EST
PRESS RELEASESRevance To Participate In The 38th Annual J.P. Morgan Healthcare ConferenceBy Business WireJan 9, 2020 4:05 PM EST
PRESS RELEASESRevance Provides Corporate Update And Anticipated Milestones For 2020By Business WireJan 9, 2020 8:05 AM EST
PRESS RELEASESRevance Announces Proposed Public Offering Of Common StockBy Business WireDec 3, 2019 11:01 AM EST
STOCKSAllergan CEO: Botox is in a very strong position despite growing competitionBy Armie Margaret LeeSep 5, 2018 2:24 PM EDT
MARKETSAllergan's Meury talks market expansion in aestheticsBy Armie Margaret LeeMay 17, 2018 4:18 PM EDT
JIM CRAMERTechnology Is Fueling Gains: Cramer's 'Mad Money' RecapBy Scott RuttApr 19, 2018 6:27 AM EDT
MARKETSBiosimilar Pipeline Among Areas of Shareholder Focus at Mylan's Investor DayBy Armie Margaret LeeApr 10, 2018 5:19 PM EDT
MERGERS AND ACQUISITIONSAllergan CEO: We Are Looking at All Options to Create Shareholder ValueBy Armie Margaret LeeMar 15, 2018 7:35 AM EDT
STOCKSMylan shares surge as analyst says it's poised to gain share from rivalsBy Armie Margaret LeeMar 6, 2018 12:13 PM EST
STOCKSWith Botox getting another rival, will Allergan strike a major deal?By Armie Margaret LeeMar 1, 2018 5:30 PM EST
STOCKSAllergan exec on medical aesthetics: 'The future is about market expansion'By Armie Margaret LeeFeb 15, 2018 7:47 PM EST
HEALTHRivals Unlikely to Knock Allergan's Botox Off its Perch: AnalystBy Armie Margaret LeeJan 29, 2018 5:58 PM EST
STOCKSAllergan's Botox Business Could Stave Off Competition by Inking This Deal: RBCBy Kinsey GrantJan 25, 2018 7:30 AM EST
OPINIONAllergan Ends Positive After Selloff; Walgreens, Fred's Make Moves -- ICYMIBy Michael BrownDec 6, 2017 7:56 PM EST
STOCKSAllergan shares tumble as Revance reports positive data for Botox rivalBy Armie Margaret LeeDec 5, 2017 12:41 PM EST
